© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Biosimilars
OptumRx to Cover Amgen’s Biosimilar of Humira
November 18, 2022
OptumRx will offer Amjevita and two other biosimilars alongside Humira. OptumRx is the first large PBM to make public its plans for the seven Humira biosimilars that may come on the market next year.
No Need for Biosimilar-to-Biosimilar Switching Studies, Authors Conclude
October 20, 2022
The question of whether it is safe to switch among biosimilars, not just between biosimilars and the reference product, is coming more pertinent as the number of biosimilars on the market increases.
Investigators Report High Similarity Between NovoLog and Biosimilar Candidate
October 20, 2022
A phase 3 trial sponsored by the biosimilar maker shows that its candidate, temporarily named MYL-1601D, has the same immunogenicity, efficacy and safety levels as NovoLog, Novo Nordisk’s brand-name insulin aspart. Novolog and its authorized generic currently have the U.S. insulin aspart market to themselves.
Three Biosimilars on the Market and Hadlima To Come
October 10, 2022
Samsung Bioepis executive Tom Newcomer’s touts the 10-year-old biosimilar company’s achievements as it gets ready to launch its Humira biosimilar, Hadlima.
Hadlima is Getting Into Interchangeability Game
October 07, 2022
Hadlima is scheduled to be on to the market in July 2023. In an interview with Managed Healthcare Executive®, a Samsung Bioepis executive says data on Hadlima’s interchangeability won’t be ready till 2024.
No Word on Price. But Hadlima, on the Market in 27 Countries, ‘Has Experience,’ Says Samsung Bioepis Executive
October 06, 2022
Tom Newcomer, head of U.S. market access for the maker of Humira biosimilar Hadlima, deflected questions on price but touted the drug’s track record overseas.
Some Humira Biosimilar Customers Are Taking a Wait-and-See Approach
October 06, 2022
Tom Newcomer, head of U.S. market access for Samsung Bioepis, maker of Hadlima, a Humira biosimilar, said some potential customers want to see which biosimilars will grab a large market share before deciding on which one to buy
Implications of Multiple Switching with Biologic Therapies
September 23, 2022
Study-based findings provide support for considerable implications of multiple switching between biosimilar and originator products.
Biosimilar Discontinuation Rates Are High But Comparable to Those for Reference Biologics: Review
September 14, 2022
The review focused on Remicade (infliximab) and Enbrel (etanercept). The annualized discontinuation rate was 21% among patients who had undergone nonmedical switching to biosimilars. However, the rates were similar to those found in some separate analyses of patients on reference biologics.
How the Inflation Reduction Act May Affect Biosimilars
September 13, 2022
Several provisions in the law are designed to protect and foster the biosimilar market. But some representatives of the sector see CMS drug price negotiation as a threat to profit margins.